Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial

Article Cardiac & Cardiovascular Systems

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Paul A. Heidenreich et al.

Summary: The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure provides patient-centric recommendations for the prevention, diagnosis, and management of heart failure, based on contemporary evidence and updated recommendations.

CIRCULATION (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology

Wilfried Mullens et al.

Summary: Novel pharmacologic treatment options reduce mortality and morbidity in patients with heart failure, despite the concerns about potential risks to renal function. These treatments have been shown to be beneficial even in patients with poor renal function.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics

Wilfried Mullens et al.

Summary: The ADVOR trial recruited 519 acute heart failure patients to investigate the efficacy of acetazolamide in improving decongestion on top of standard loop diuretics. The study found that the participants were older with higher levels of NT-proBNP, reflecting the real-world clinical situation.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Medicine, General & Internal

Acetazolamide in Acute Decompensated Heart Failure with Volume Overload

Wilfried Mullens et al.

Summary: The addition of acetazolamide to loop diuretic therapy in patients with acute decompensated heart failure results in a higher incidence of successful decongestion without increasing adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF

John R. Teerlink et al.

Summary: In heart failure patients, omecamtiv mecarbil produces greater therapeutic benefit as baseline ejection fraction decreases, particularly in patients with lower baseline EF.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems